Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
about
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesModern approaches to HLA-haploidentical blood or marrow transplantationEffects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML PatientsThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAlternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaMinimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisHematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationPediatric chronic myeloid leukemia is a unique disease that requires a different approachAnti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Primary Immune Deficiency Treatment Consortium (PIDTC) update.Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in a Patient with Chronic Granulomatous Disease and Active Infection: A First Report.T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant.Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
P2860
Q26751959-27B3E4C6-1304-4E18-917D-31FD3E261CF4Q26797506-D1D027FD-3D15-4AFF-A25D-9DDF159A3F77Q26799602-722C883A-4398-4E38-80E8-B2B0DE2A89E9Q28076264-831381EE-F9B3-401F-B944-5B825FBBE6EBQ28080943-5FCBB033-7C8B-47E0-B241-AE713EDABB8BQ33815986-E6F013BC-40BE-421D-96D5-1AD183F6BCCCQ35924098-5804EDF3-2594-4B57-8AAE-D23F25290822Q36040293-1867A4E7-AD80-4756-AB77-7836271FA856Q36445665-4CAD48B3-7529-462C-8FF4-D1C1F5EFE5E7Q36703516-205D2053-7A1A-450B-9D84-C280BC5183F5Q36833808-8B86B35D-D225-4CF0-8893-3638EB912361Q37025981-B1A5F13F-04B4-440F-AC70-3458F6C20FFEQ37618811-6FC26FEA-6670-45D0-A6A3-90E1A6C4B558Q37618838-DD0A40AF-1A94-4549-8605-B92756FF803BQ38381708-D35D4A94-89AD-47A2-BD3E-53B1EC28E7DDQ38735833-C47FAAFD-F1AD-47D4-AA5B-3682DC449DB5Q38742863-1C597430-8E8E-4CF9-B05C-A3E18853DD2CQ38742867-31EBFC19-535F-4085-88AE-4F13CDD5E50AQ38815399-5465FCCE-FF3A-4AEA-A068-7FEEA56C2BC0Q38855061-59DBF397-6FBF-4AFC-B2A8-84011CDA2430Q39036486-E6C86EA4-4B40-4DA5-AB44-A2DE45CD7D0BQ39042251-E0969EE2-F4C2-4A65-A532-0673537132D3Q39232385-291205A1-ACCB-49B4-82A0-174B015FF823Q39351385-832469E3-F18E-4D77-ABEA-53FF78FBC29BQ40296052-637BFE70-6220-475F-947F-51134BFC1114Q40496183-FFD8A6F7-5615-4DFF-A195-F1FADE0F9062Q40657274-BB638977-4170-4AE0-A0BB-82628B671242Q40959068-D14DCE25-F95D-4DA3-9CD1-06515A432EC8Q41138074-5235F662-F086-4822-93FB-11A6CF25B5E5Q43272332-0BB2D27D-3C0D-4BE5-A67A-A40ACE78C431Q48103108-4F5F2297-F582-42A4-9DF4-9820665EFBBDQ49791828-7060384E-8E34-4716-AF06-C97D43D1D8B6Q50966214-D12FF2AE-1337-4D7D-A88A-BE213D26FB00Q52763837-C080D527-A91A-4C75-8E2E-0DFF9EA7D893Q52927960-24EF2DE2-8569-4482-A52F-D9DF1619ECEEQ53824120-4CAF11DB-4D74-4EE0-809C-CE5763AC8EA0Q53979038-F6803E1B-28F0-414F-A619-B0A9F2226F1AQ55240175-25240E48-D5F4-4D74-818F-725616FE1B51
P2860
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@ast
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@en
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@nl
type
label
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@ast
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@en
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@nl
prefLabel
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@ast
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@en
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@nl
P2093
P2860
P1433
P1476
Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.
@en
P2093
Amy E DeZern
B Douglas Smith
Carol Ann Huff
Christopher G Kanakry
Douglas E Gladstone
Ephraim J Fuchs
Gary L Rosner
Hua-Ling Tsai
Ivan Borrello
Ivana Gojo
P2860
P304
P356
10.1182/BLOOD-2014-07-587477
P407
P577
2014-10-14T00:00:00Z